Echinocandins in the control of infections associated to polymicrobial biofilms of Candida spp. and bacteria such as Stapholococcus aureus and Pseudomonas aeruginosa

• Grant number: 17/19374-9
• Support Opportunities: Regular Research Grants
• Start date: July 01, 2018
• End date: September 30, 2020
• Field of knowledge: Biological Sciences - Pharmacology - General Pharmacology
• Principal Investigator: Kelly Ishida
• Grantee: Kelly Ishida
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Fungi and bacteria often coexist in polymicrobial biofilms and represent a clinically relevant health problem. Among fungal species Candida albicans is the most frequent in the hospital setting and it is estimated that 27% of C. albicans bloodstream infections (BIs) are polymicrobial, wherein Stapholococcus aureus and Pseudomonas aeruginosa sre the common bacterial species isolated together with C albicans. In Brazil, the mortality rate of patients diagnosed with polymicrobial BIs reaches 45.7%. The treatment of polymicrobial infections is difficult to diagnose and has implications for the selection of antimicrobial therapy and the expected response to treatment, especially when it involves the presence of multiresistant microorganisms and the formation of biofilms. Biofilm formation is an important virulence factor, as it is generally related to the chronicity of infection and increased antimicrobial tolerance. Polymers of ² (1,3) D-glucan, component of the fungal cell wall, and the major component of the extracellular matrix of C. albicans biofilms; is also expressed as periplasmic glucan of P. aeruginosa and extracellular matrix component of S. aureus and P. aeruginosa biofilms. Strategies such as the use of echinocandins, inhibitors of ² (1,3) D-glucan synthesis, in the treatment of polymicrobial infections of C. albicans and P. aeruginosa / S. aureus can improve the outcomes of these infections, reduce side effects and costs, and is an innovative choice for the treatment of mixed infection. In this context, we aim to evaluate the effect of echinocandins on monomicrobial and mixed biofilms of C. albicans and bacteria such as P. aeruginosa and S. aureus. (AU)

Scientific publications

(14)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

COSTA-FERNANDEZ, SANDRA; MATOS, JENYFFER K. R.; SCHEUNEMANN, GABY S.; SALATA, GIOVANNA C.; CHORILLI, MARLUS; WATANABE, IL-SEI; DE ARAUJO, GABRIEL L. B.; SANTOS, MARINILCE F.; ISHIDA, KELLY; LOPES, LUCIANA B.. Nanostructured lipid carriers containing chitosan or sodium alginate for co-encapsulation of antioxidants and an antimicrobial agent for potential application in wound healing. International Journal of Biological Macromolecules, v. 183, p. 668-680, JUL 31 2021. (14/50928-2, 19/26048-6, 13/16617-7, 15/07993-0, 17/19374-9, 18/13877-1)

SPADARI, CRISTINA DE CASTRO; WIRTH, FERNANDA; LOPES, LUCIANA BIAGINI; ISHIDA, KELLY. New Approaches for Cryptococcosis Treatment. MICROORGANISMS, v. 8, n. 4, APR 2020. (17/19374-9, 18/12149-2, 18/13877-1)

WIRTH, FERNANDA; ISHIDA, KELLY. Antifungal drugs: An updated review of central nervous system pharmacokinetics. MYCOSES, v. 63, n. 10, SEP 2020. (17/19374-9)

ARGOMEDO, LUIS M. Z.; BARROSO, VINICIUS M.; BARREIRO, CRISTIANE S.; DARBEM, MARIANA P.; ISHIDA, KELLY; STEFANI, HELIO A.. Novel 2-Aryloxazoline Compounds Exhibit an Inhibitory Effect on Candida spp., Including Antifungal-Resistant Isolates. ACS Medicinal Chemistry Letters, v. 11, n. 12, p. 2470-2475, DEC 10 2020. (18/11612-0, 17/19374-9)

FERNANDES, LUCIANA; FORTES, BRUNA NAKANISHI; LINCOPAN, NILTON; ISHIDA, KELLY. Caspofungin and Polymyxin B Reduce the Cell Viability and Total Biomass of Mixed Biofilms of Carbapenem-Resistant Pseudomonas aeruginosa and Candida spp.. FRONTIERS IN MICROBIOLOGY, v. 11, DEC 16 2020. (17/26076-4, 17/19374-9)

BARRETO, THAYNA LOPES; ROSSATO, LUANA; DUARTE DE FREITAS, ALINE LUIZA; MEIS, JACQUES F.; LOPES, LUCIANA BIAGINI; COLOMBO, ARNALDO LOPES; ISHIDA, KELLY. Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, v. 56, n. 2, AUG 2020. (17/19374-9, 18/13877-1, 18/03708-8, 17/15226-5, 17/02203-7, 17/19095-2)

FORTES, BRUNA NAKANISHI; SCHEUNEMANN, GABY; MELO, ANALY SALLES DE AZEVEDO; ISHIDA, KELLY. Caspofungin alone or combined with polymyxin B are effective against mixed biofilm of Aspergillus fumigatus and carbapenem-resistant Pseudomonas aeruginosa. Research in Microbiology, v. 174, n. 1-2, p. 9-pg., 2023-01-01. (17/26076-4, 17/19374-9, 20/11486-5)

ROSSATO, LUANA; DOS SANTOS, MARIELLE CAMARGO; VITALE, ROXANA G.; DE HOOG, SYBREN; ISHIDA, KELLY. Alternative treatment of fungal infections: Synergy with non-antifungal agents. MYCOSES, v. 64, n. 3, NOV 2020. (17/19374-9)

MENDES DA SILVA DE BASTIANI, FERNANDA WALT; SPADARI, CRISTINA DE CASTRO; ROCHA DE MATOS, JENYFFER KELLY; SALATA, GIOVANNA CASSONE; LOPES, LUCIANA BIAGINI; ISHIDA, KELLY. Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis. FRONTIERS IN MICROBIOLOGY, v. 10, JAN 10 2020. (17/19374-9, 15/07993-0, 18/13877-1)

PASSOS, JULIA SAPIENZA; DE MARTINO, LUIZA CAPELLO; CARVALHO DARTORA, VANESSA FRANCO; DE ARAUJO, GABRIEL L. B.; ISHIDA, KELLY; LOPES, LUCIANA B.. Development, skin targeting and antifungal efficacy of topical lipid itraconazole. European Journal of Pharmaceutical Sciences, v. 149, JUN 15 2020. (17/04174-4, 14/50928-2, 17/19374-9, 15/07993-0, 18/13877-1, 13/16617-7)

SCHEUNEMANN, GABY; FORTES, BRUNA N.; LINCOPAN, NILTON; ISHIDA, KELLY. aspofungin Inhibits Mixed Biofilms of Candida albicans and Methicillin-Resistant Staphylococcus aureus and Displays Effectiveness in Coinfected Galleria mellonella Larva. MICROBIOLOGY SPECTRUM, v. 9, n. 2, OCT 2021. (17/26076-4, 17/19374-9)

BARRETO, THAYNA L.; LOPES, LUCIANA B.; MELO, ANALY S. A.; ISHIDA, KELLY. In vivo synergism of free miltefosine or in alginate-based nanocarrier combined with voriconazole on aspergillosis. FUTURE MICROBIOLOGY, v. 16, n. 15, OCT 2021. (17/19374-9, 15/07993-0, 18/03708-8, 18/13877-1)

YUKUYAMA, MEGUMI NISHITANI; ISHIDA, KELLY; BARROS DE ARAUJO, GABRIEL LIMA; SPADARI, CRISTINA DE CASTRO; DE SOUZA, ALINE; LOBENBERG, RAIMAR; BAZAN HENOSTROZA, MIRLA ANALI; FOLCHINI, BEATRIZ RABELO; PERONI, CAMILLA MIDORI; CAMASMIE PETERS, MARIA CHRISTINA; et al. y Rational design of oral flubendazole-loaded nanoemulsion for brain delivery in cryptococcosis. COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, v. 630, DEC 5 2021. (18/12149-2, 17/19374-9, 18/22713-2)

BORBA-SANTOS, LUANA PEREIRA; BARRETO, THAYNA LOPES; VILA, TAISSA; CHI, KUNG DARH; MONTI, FABIANA DOS SANTOS; DE FARIAS, MARCONI RODRIGUES; ALVIANO, DANIELA S.; ALVIANO, CELUTA S.; FUTURO, DEBORA O.; FERREIRA, VITOR; et al. In Vitro and In Vivo Antifungal Activity of Buparvaquone against Sporothrix brasiliensis. Antimicrobial Agents and Chemotherapy, v. 65, n. 9, SEP 2021. (17/19374-9)